FDA 483 - Corixa Corporation d.b.a. GlaxoSmithKline - March 04, 2022
FDA 483 for Corixa Corporation d.b.a. GlaxoSmithKline on March 04, 2022. Product: drugs. Access full analysis and detailed observations.
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
FDA 483 for Corixa Corporation d.b.a. GlaxoSmithKline on March 04, 2022. Product: drugs. Access full analysis and detailed observations.
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Inspection Date
March 4, 2022
Product Type
drugs
ID: 66b7f6dc-5234-4cb2-9241-fd571a6609fb
View on DashboardTransform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox